Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › apremilast

apremilast

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of apremilast

44 trials tracked of apremilast: 22 in phase 3 or 4 and 14 with published results. The most-cited published study has 204 citations.

44Trials tracked
22Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 10 Phase 3 12 Phase 2 17 Phase 1 4 Other / NA 1
  1. Phase 3 A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease Completed · 204 cited
  2. Phase 3 Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients Completed · 152 cited
  3. Phase 4 A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. Completed · 59 cited
  4. Phase 3 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy Completed · 54 cited
  5. Phase 3 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp Completed · 47 cited
  6. Phase 4 Vascular Inflammation in Psoriasis - Apremilast Completed · 44 cited
Show 38 more trials
  1. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 38 cited
  2. Phase 3 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis Completed · 38 cited
  3. Phase 3 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis Completed · 25 cited
  4. Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Completed · 21 cited
  5. Phase 3 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy Completed · 12 cited
  6. Phase 4 A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis Completed · 9 cited
  7. Phase 3 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP) Completed · 5 cited
  8. Phase 4 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life Completed · 2 cited
  9. Phase 4 Apremilast in Palmo-Plantar Psoriasis Completed
  10. Phase 4 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis Completed
  11. Phase 4 Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy Completed
  12. Phase 4 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Completed
  13. Phase 4 Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Completed
  14. Phase 3 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Completed
  15. Phase 3 Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis. Completed
  16. Phase 3 Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis Completed
  17. Phase 2 Study of Apremilast in Atopic or Contact Dermatitis Completed
  18. Phase 2 Apremilast for Atopic Dermatitis - A Pilot Study in Adults Completed
  19. Phase 2 Apremilast for Erythema Multiforme Completed
  20. Phase 2 Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis Completed
  21. Phase 2 Open Label Pilot Study of Apremilast in Treatment of Rosacea Completed
  22. Phase 2 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis Completed
  23. Phase 2 Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis Completed
  24. Phase 2 Medication Development in Alcoholism: Apremilast Versus Placebo Completed
  25. Phase 2 Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis Completed
  26. Phase 2 Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis Completed
  27. Phase 2 Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast Completed
  28. Phase 2 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis Completed
  29. Phase 2 Spondylitis Trial of Apremilast for Better Rheumatic Therapy Completed
  30. Phase 2 Apremilast 30 mg Twice Daily (BID) Combined With Dupilumab Completed
  31. Phase 2 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS) Completed
  32. Phase 2 Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis Completed
  33. Phase 2 A Study Examining the Medication Apremilast as Treatment for Chronic Itch Completed
  34. Phase 1 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects Completed
  35. Phase 1 A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast Completed
  36. Phase 1 Effects of Age and Sex on the Pharmacokinetics of Apremilast in Healthy Adults Completed
  37. Phase 1 Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Adults Completed
  38. N/A Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome
Diabetes & Endocrinology Sys. Review
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome One case report links secukinumab to severe capillary leak syndrome in a woman with psoriasis
This case report details the clinical course of a 66-year-old woman with new-onset erythrodermic psoriasis who developed systemic capillary …
A woman with psoriasis developed life-threatening capillary leak syndrome after starting secukinumab, with symptoms improving only after sto…
Frontiers Apr 21, 2026
Retrospective FAERS analysis reveals sex-specific adverse event patterns for apremilast, crisaborole, and roflumilast in chronic inflammatory diseases
Drug Pipeline Cohort
Retrospective FAERS analysis reveals sex-specific adverse event patterns for apremilast, crisaborole, and roflumilast in chronic inflammatory diseases Why Side Effects Hit Men and Women Differently
This retrospective pharmacovigilance study analyzed 127,516 apremilast reports, 7,562 crisaborole reports, and 2,142 roflumilast reports wit…
A massive new analysis reveals that common anti-inflammatory drugs cause different side effects in men and women, meaning biology is more co…
Frontiers Apr 18, 2026